Role of bronchoalveolar lavage in immunocompromised patients with pneumonia treated with a broad spectrum antibiotic and antifungal regimen

I A Hohenadel, M Kiworr, R Genitsariotis, D Zeidler, J Lorenz, I A Hohenadel, M Kiworr, R Genitsariotis, D Zeidler, J Lorenz

Abstract

Background: In a retrospective study the value of bronchoalveolar lavage (BAL) in the diagnosis of pneumonia was investigated in 95 immunocompromised patients suffering from haematological disorders and receiving a regimen of broad spectrum antibiotics and antifungal agents (BSAR).

Methods: With the exception of four afebrile patients, all had fever, raised C reactive protein (CRP) levels, and new infiltrates visible on chest radiography. All patients underwent BAL to identify the organism causing the pneumonia and surveillance cultures were performed regularly for pathogens at different sites. Following classification of the isolates, patients with positive cultures were subdivided into two groups, pathogenic or contaminated. We investigated whether relevant pathogens were cultured only from the BAL fluid and whether they were susceptible to BSAR.

Results: Although 77 of the 95 patients were thrombocytopenic, bleeding during BAL occurred in only 15% of all patients. Ten days after the procedure the fever improved in 88% of patients, radiographic findings improved in 71%, and CRP levels improved in 75% of patients; 22% of patients died within 28 days. Pathologically relevant isolates were found in 65% of all patients. Respiratory pathogens were detected only in the BAL fluid of 29 of the 95 patients (35% Gram positive species, 40% Gram negative species, 11% Mycobacterium, 11% fungi, and 3% cytomegalovirus). In 16 of these 29 patients (55%) the pathogens cultured only from the BAL fluid were resistant to treatment. Pathogens detected only in the BAL fluid were not susceptible to a standard broad spectrum antibiotic and antifungal regimen including teicoplanin, ceftriaxon, tobramycin, and amphotericin B in 12 of the 29 patients (41%).

Conclusions: Our data suggest that 12 patients were treated with broad spectrum antimicrobial agents which were not directed at the appropriate organism on in vitro sensitivity tests without BAL. BAL is a relatively safe procedure in the diagnosis of pneumonia, supplying important information in immunocompromised patients as well as in immunocompromised patients receiving BSAR.

References

    1. Chest. 1976 Nov;70(5):584-8
    1. West J Med. 1979 Jul;131(1):4-7
    1. Am J Pathol. 1979 Oct;97(1):149-206
    1. Ann Intern Med. 1982 Jan;96(1):1-10
    1. J Clin Pathol. 1984 Apr;37(4):390-7
    1. Medicine (Baltimore). 1984 May;63(3):155-64
    1. Ann Intern Med. 1984 Jul;101(1):1-7
    1. Mayo Clin Proc. 1985 Jul;60(7):473-87
    1. Am Rev Respir Dis. 1985 Nov;132(5):1118-23
    1. Am J Med. 1986 Aug;81(2):249-54
    1. Am J Clin Pathol. 1986 Oct;86(4):518-23
    1. Am Rev Respir Dis. 1987 Jan;135(1):250-63
    1. Mayo Clin Proc. 1987 Jul;62(7):549-57
    1. Arch Intern Med. 1988 Apr;148(4):953-5
    1. J Clin Microbiol. 1988 Jun;26(6):1150-5
    1. Chest. 1988 Oct;94(4):745-9
    1. Klin Wochenschr. 1990 Apr 2;68(7):372-9
    1. Chest. 1993 Nov;104(5):1400-7
    1. Eur J Haematol. 1993 Oct;51(4):256-8
    1. Infection. 1993 Sep-Oct;21(5):291-6
    1. Cancer. 1994 May 1;73(9):2296-304
    1. Med Klin (Munich). 1994 Mar 15;89(3):114-23
    1. Infect Control Hosp Epidemiol. 1994 Feb;15(2):101-4
    1. Eur J Haematol. 1995 Mar;54(3):157-62
    1. Am J Med. 1996 Jun 24;100(6A):3S-12S
    1. JAMA. 1995 Aug 23-30;274(8):639-44

Source: PubMed

3
Subskrybuj